BioSpace News Archive

Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has expanded its Clinical Advisory Board with the appointment of ophthalmology expert and innovator, Miguel González-Andrades, MD, PhD.

CyGenica has announced that it has raised USD $1.4 million in a seed fund investment round, led by global venture capital investor SOSV.

Viveve Medical, Inc. today announced that the United States Patent and Trademark Office (USPTO) recently issued U.S. Patent No. 10,980,596 for Viveve’s dual-energy technology device.

AUM LifeTech, Inc., a preclinical stage biotechnology company, announced today that it has been selected by the National Institutes of Health (NIH) to present an update on their drug development pipeline at 2021 BIO Digital, the premier biotech event

Oncology Analytics, a leading data analytics and technology-enabled service company purpose-built for oncology, has released its Q1 2021 quarterly report on the FDA’s newly approved anti-cancer drugs and indications and noted a significant increase in approvals from the final quarter of 2020.

Longhorn Vaccines & Diagnostics announced today that it has been selected to deliver a presentation on the past success and future opportunities for its lead product, PrimeStore MTM.

Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations, will be exhibiting at BIO Digital 2021, the world’s largest virtual biotech partnering and education event.

Vektor Medical, Inc. announced that a dual-center study reports that vMap™, as part of a new, non-invasive workflow, improved efficiency and precision for radio-ablation therapy in the six studied patients.

Viewpoint Molecular Targeting, Inc., a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, announced it has initiated patient enrollment and screening in its Phase 1 imaging study evaluating VMT01 for the treatment of metastatic melanoma.

The market is estimated to grow with a CAGR of 7.3% from 2020 to 2027.